
Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.
At the 2022 Maui Derm NP+PA meeting in Colorado Springs, Colorado, a discussion of the newest biologics and how to "mix and match" medications and algorithms.
Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego, professor of dermatology and pediatrics and vice-chair of the department of dermatology at UC San Diego School of Medicine, discussed the evaluation and use of new medications for atopic dermatitis for children, and how you need to "mix and match" biologics and alogrithms for optimal results.






